AI¿Í GLP-1ÀÇ ¼ºÀå ±âȸ´Â Á¦2Çü ´ç´¢º´(T2D) Ä¡·á ±â±â È®´ë¸¦ ÃËÁø
ÀÌ º¸°í¼´Â Áö¿ª °£ ´ç´¢º´ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ´Â ¼¼°è ´ç´¢º´ Ä¡·á ±â±â »ê¾÷¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ °³¿ä¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ±âÁ¸ ±â¾÷°ú ½Å»ý ½ºÅ¸Æ®¾÷À¸·Î ±¸¼ºµÇ¾î Ä¡¿ÇÑ °æÀïÀ» ¹úÀ̰í ÀÖÀ¸¸ç, OEM ¾÷üµéÀº ´ç´¢º´ Ä¡·á¸¦ °ÈÇÏ°í °í°´ÃþÀ» Á¦1Çü ´ç´¢º´(T1D) ȯÀÚ»Ó¸¸ ¾Æ´Ï¶ó Á¦2Çü ´ç´¢º´(T2D), ¿¹ºñ ´ç´¢º´ ȯÀÚ ¹× ºñ´ç´¢º´ ȯÀÚ±îÁö È®´ëÇϱâ À§ÇØ Çõ½ÅÀûÀÎ AI ±â¼úÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ¾ÈÁ¤ÀûÀÎ ¼öÀÍ¿øÀ» âÃâÇϰí ȯÀÚÀÇ °æÁ¦Àû ºÎ´ãÀ» ´ú¾îÁÖ´Â »õ·Î¿î ºñÁî´Ï½º Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ Á¶»ç´Â ´ç´¢º´ Ä¡·á ±â±â¸¦ Ç÷´ç ¸ð´ÏÅ͸µ°ú Àν¶¸° Àü´ÞÀÇ µÎ °¡Áö ÁÖ¿ä ¹üÁÖ·Î ºÐ·ùÇß½À´Ï´Ù. Ç÷´ç ¸ð´ÏÅ͸µ ±â±â´Â ÀÚ°¡ Ç÷´ç ¸ð´ÏÅ͸µ(SMBG) ÀåÄ¡¿Í Áö¼ÓÀû Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛÀ¸·Î ±¸¼ºµÇ¸ç, Àν¶¸° Àü´Þ ÀåÄ¡´Â Àν¶¸° ÆßÇÁ¿Í Àν¶¸° ÆæÀ¸·Î ±¸¼ºµË´Ï´Ù. ¶ÇÇÑ ´ç´¢º´ À¯Çü(T1D¿Í T2D)¿¡ µû¶ó ¾÷°è¸¦ ¼¼ºÐÈÇÏ¿© °¢°¢ °íÀ¯ÇÑ ½ÃÀå µ¿ÇâÀ» È®ÀÎÇß½À´Ï´Ù. Áö¸®Àû ¹üÀ§´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç(APAC), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ³²¾Æ½Ã¾Æ(MEASA), ¶óƾ¾Æ¸Þ¸®Ä«¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ Á¶»ç´Â ¸ðµç ºÎ¹®¿¡ ´ëÇÑ °ü·Ã ¿¹Ãø, Å©±â Á¶Á¤ ¹× µ¿Ç⠺м®À» Á¦°øÇÕ´Ï´Ù. °æÀï ȯ°æÀ» Á¶»çÇϰí ÀÌ ºÐ¾ß¿¡¼ ¿µÇâ·ÂÀ» Çà»çÇÏ´Â ÁÖ¿ä ±â¾÷ ¹× ÁÖ¿ä ±â¼úÀ» °Á¶ÇÕ´Ï´Ù. °¢ ºÎ¹®ÀÇ ¼ºÀå ÃËÁø ¹× ¾ïÁ¦¿äÀÎÀ» ÆÄ¾ÇÇϰí, ÀÌ »ê¾÷ÀÇ º¯È·Î ÀÎÇÑ ±âȸ¸¦ ºÐ¼®ÇÕ´Ï´Ù. ±âÁØ ¿¬µµ´Â 2023³â, ¿¹Ãø ±â°£Àº 2024-2028³âÀÔ´Ï´Ù.
¸ñÂ÷
Àü·«Àû ¿øÄ¢
- ¿Ö ¼ºÀåÀÌ ¾î·Á¿öÁö´Â°¡?
- The Strategic Imperative 8(TM)
- ´ç´¢º´ Ä¡·á ±â±â ¾÷°è¿¡ ´ëÇÑ ÁÖ¿ä Àü·«Àû ¿øÄ¢ÀÇ ¿µÇâ
- Growth Pipeline Engine(TM)À» ÃËÁøÇÏ´Â ¼ºÀå ±âȸ
¼ºÀå ±âȸ ºÐ¼®
- ºÐ¼® ¹üÀ§
- ¼¼ºÐÈ
- ÁÖ¿ä °æÀï»ç
- ¼ºÀå ÁöÇ¥
- À¯Åë ä³Î
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ¿¹Ãø °¡Á¤
- ¸ÅÃâ ¿¹Ãø
- Áö¿ªº°, ¸ÅÃâ ¿¹Ãø
- ºÎ¹®º°, ¸ÅÃâ ¿¹Ãø
- ¸ÅÃâ ¿¹Ãø ºÐ¼®
- °¡°Ý µ¿Çâ°ú ¿¹Ãø ºÐ¼®
- ºÎ¹®º°, ¸ÅÃâ Á¡À¯À²
- °æÀï ȯ°æ
- ¸ÅÃâ Á¡À¯À²
- ¸ÅÃâ Á¡À¯À² ºÐ¼®
´ç´¢º´ Ä¡·á µ¿Çâ
- ¼¼°èÀÇ ´ç´¢º´ À¯º´·ü
- »õ·Î¿î ºñÁî´Ï½º ¸ðµ¨
- Ä¡·á ȯ°æ µ¿Çâ
- ģȯ°æ °ü¸®
- ¸ÞŸº¼¸¯ Çコ
- »õ·Î¿î Àν¶¸° Àü´Þ ½Ã½ºÅÛ
- ´ç´¢º´ Ä¡·áÀÇ AI ÅëÇÕ
T1D ±âȸ
- T1D ȯÀÚ ¿©Á¤
- Áß±¹ÀÇ T1D ¼Ò¾Æ¡¤Ã»¼Ò³â ȯÀÚ
- ¼ºÀå ±âȸ : Áß±¹ÀÇ T1D ¼Ò¾Æ¡¤Ã»¼Ò³â ȯÀÚ¿ë CGM
- Áß±¹ : ½ÃÀå ºÐ¼®°ú º¸±Þ Á¢±Ù¹ý
- T1D ȯÀÚ ¿ä±¸¿¡ ´ëÀÀÇÏ´Â ±âŸ ¹æ¹ý
T2D ±âȸ
- T2D ȯÀÚ ¿©Á¤
- ¼¼°èÀÇ T2D À¯º´·ü
- T2D : ¼¼°èÀÇ °Ç° ¹®Á¦
- T2D »óȯ
- GLP-1¿¡ ÀÇÇÑ T2D ±âȸ
- Àν¶¸° ÆßÇÁ°¡ T2DÀÇ ¼ºÀå ±âȸ
½ÅÈï ±â¾÷
- Diabeloop¿¡ ÀÇÇÑ Àν¶¸° Àü´Þ DBLG1 ¾Ë°í¸®Áò
- Decide Clinical Software¿¡ ÀÇÇÑ GlucoTab
¼ºÀå ±âȸ ºÐ¼® : SMBG
- SMBG ¼ºÀå ÁöÇ¥
- SMBG ¼ºÀå ÃËÁø¿äÀÎ
- SMBG ¼ºÀå ¾ïÁ¦¿äÀÎ
- SMBG ¸ÅÃâ ¿¹Ãø
- SMBG ¸ÅÃâ ¿¹Ãø, Áö¿ªº°
- SMBG °æÀï»ç
- SMBG ¿¹Ãø ºÐ¼®
¼ºÀå ±âȸ ºÐ¼® : CGM
¼ºÀå ±âȸ ºÐ¼® : Àν¶¸° Ææ
¼ºÀå ±âȸ ºÐ¼® : Àν¶¸° ÆßÇÁ
¼ºÀå ±âȸ À¯´Ï¹ö½º
- ¼ºÀå ±âȸ 1 : T2D ȯÀÚ¿ë Àν¶¸° ÆßÇÁ
- ¼ºÀå ±âȸ 2 : ±Û·çÄÚ½º¿Í ÁöÁúÀÇ ¸ÖƼÆÄ¶ó¹ÌÅÍ °Ë»ç¿ë ¿þ¾î·¯ºí
- ¼ºÀå ±âȸ 3 : ģȯ°æ Àν¶¸° Ææ
- ¼ºÀå ±âȸ 4 : Áß±¹ÀÇ T1D ¼Ò¾Æ¡¤Ã»¼Ò³â ȯÀÚ¿ë CGM
- ¼ºÀå ±âȸ 5 : AI ±â¹Ý Á¶±â Áø´Ü Åø°ú °Ë»ç
´ÙÀ½ ½ºÅÜ
ksm
Growth Opportunities in AI and GLP-1 will Drive the Expansion of Type 2 Diabetes Devices
This study provides a detailed overview of the global diabetes care device industry, which is witnessing a significant increase in demand due to the growing prevalence of diabetes across regions. The market, comprising both established players and emerging start-ups, is the site of fierce competition. OEMs are developing innovative, AI-equipped technology to enhance diabetes care and expand the customer base beyond patients with type 1 diabetes (T1D) to those with type 2 diabetes (T2D), prediabetes, and even those without diabetes. Companies are adopting novel business strategies that create steady revenue streams and ease patients' financial burdens. The study segments diabetes care devices into two main categories: glucose monitoring and insulin delivery. Glucose monitoring devices comprise self-monitoring of blood glucose (SMBG) devices and continuous glucose monitoring (CGM) systems, while insulin delivery devices comprise insulin pumps and insulin pens. The study also segments the industry according to diabetes type (T1D and T2D), examining the unique market dynamics of each. The geographic scope includes North America, Europe, Asia-Pacific (APAC), the Middle East, Africa, and South Asia (MEASA), and Latin America. The study provides relevant forecast, sizing, and trend analyses across all segments. It examines the competitive landscape and highlights the key players and significant technologies making an impact in this space. The study identifies the factors driving and restraining growth in each segment and analyzes the opportunities emerging from the changes in this industry for market players and stakeholders to leverage. The base year is 2023, and the forecast period is from 2024 to 2028.
Table of Contents
Strategic Imperatives
- Why is it Increasingly Difficult to Grow?
- The Strategic Imperative 8™
- The Impact of the Top 3 Strategic Imperatives on the Diabetes Care Device Industry
- Growth Opportunities Fuel the Growth Pipeline Engine™
Growth Opportunity Analysis
- Scope of Analysis
- Segmentation
- Key Competitors
- Growth Metrics
- Distribution Channels
- Growth Drivers
- Growth Restraints
- Forecast Assumptions
- Revenue Forecast
- Revenue Forecast by Region
- Revenue Forecast by Segment
- Revenue Forecast Analysis
- Pricing Trends and Forecast Analysis
- Revenue Share by Segment
- Competitive Environment
- Revenue Share
- Revenue Share Analysis
Trends in the Diabetes Care Continuum
- Global Diabetes Prevalence
- New Business Models
- Care Setting Trends
- Eco-friendly Management
- Metabolic Health
- New Insulin Delivery Systems
- AI Integration in Diabetes Care
T1D Opportunities
- T1D Patient Journey
- Children and Adolescents with T1D in China
- Growth Opportunity: CGM for T1D Children and Adolescents in China
- China: Market Analysis and Penetration Approach
- Additional Ways to Address T1D Patient Needs
T2D Opportunities
- T2D Patient Journey
- Global T2D Prevalence
- T2D: A Global Health Concern
- Reimbursement for T2D
- Opportunities in T2D Presented by GLP-1
- Insulin Pump Growth Opportunities in T2D
Emerging Companies
- Diabeloop's DBLG1 Algorithm for Insulin Delivery
- Decide Clinical Software's GlucoTab
Growth Opportunity Analysis: SMBG
- SMBG Growth Metrics
- SMBG Growth Drivers
- SMBG Growth Restraints
- SMBG Revenue Forecast
- SMBG Revenue Forecast by Region
- SMBG Competitors
- SMBG Forecast Analysis
Growth Opportunity Analysis: CGM
- CGM Growth Metrics
- CGM Growth Drivers
- CGM Growth Restraints
- CGM Revenue Forecast
- CGM Revenue Forecast by Region
- CGM Key Competitors
- CGM Reimbursement Trends and Market Shifts
- Diversifying CGM User Base
- CGM Forecast Analysis
Growth Opportunity Analysis: Insulin Pens
- Insulin Pen Growth Metrics
- Insulin Pen Growth Drivers
- Insulin Pen Growth Restraints
- Insulin Pen Revenue Forecast
- Insulin Pen Revenue Forecast by Region
- Insulin Pen Key Competitors
- Insulin Pen Reimbursement Trends and Market Shifts
- Insulin Pen Forecast Analysis
Growth Opportunity Analysis: Insulin Pumps
- Insulin Pump Growth Metrics
- Insulin Pump Growth Drivers
- Insulin Pump Growth Restraints
- Insulin Pump Revenue Forecast
- Insulin Pump Revenue Forecast by Region
- Insulin Pump Key Competitors
- Insulin Pump Reimbursement Trends and Market Shifts
- Insulin Pump Forecast Analysis
Growth Opportunity Universe
- Growth Opportunity 1: Insulin Pumps for T2D patients
- Growth Opportunity 2: Wearables for the Multiparametric Testing of Glucose and Lipids
- Growth Opportunity 3: Eco-friendly Insulin Pens
- Growth Opportunity 4: CGM for T1D Children and Adolescents in China
- Growth Opportunity 5: AI-based Early Diagnosis Tools and Tests
Next Steps
- Your Next Steps
- Why Frost, Why Now?
- List of Exhibits
- Legal Disclaimer